Literature DB >> 21685037

Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome.

Kenneth A Iczkowski1, Kathleen C Torkko, Gregory R Kotnis, R Storey Wilson, Wei Huang, Thomas M Wheeler, Andrea M Abeyta, Francisco G La Rosa, Shelly Cook, Priya N Werahera, M Scott Lucia.   

Abstract

Proper grading of the cribriform prostate cancer pattern has not previously been supported by outcome-based evidence. Among 153 men who underwent radical prostatectomy, 76 with prostate-specific antigen (PSA) failure (≥0.2 ng/mL [0.2 μg/L]) were matched to 77 without failure. Frequencies of high-grade patterns included fused small acini, 83.7%; papillary, 52.3%; large cribriform, 37.9%; small (≤12 lumens) cribriform, 17.0%; and individual cells, 22.9%. A cribriform pattern was present in 61% (46/76) of failures but 16% (12/77) of nonfailures (P < .0001). Multivariate analysis showed the cribriform pattern had the highest odds ratio for PSA failure, 5.89 (95% confidence interval, 2.53-13.70; P < .0001). The presence of both large and small cribriform patterns was significantly linked to failure. The cumulative odds ratio of failure per added square millimeter of cribriform pattern was 1.173 (P = .008), higher than for any other pattern. All 8 men with a cribriform area sum of 25 mm(2) or more had failure (range, 33-930). Regrading cribriform cancer as Gleason 5 improved the grade association with failure, although half of all cases with individual cells also had a cribriform pattern, precluding a precise determination of the independent importance of the latter. The cribriform pattern has particularly adverse implications for outcome.

Entities:  

Mesh:

Year:  2011        PMID: 21685037      PMCID: PMC4656017          DOI: 10.1309/AJCPZ7WBU9YXSJPE

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  34 in total

1.  Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland: a basis for checklists. Cancer Committee.

Authors:  J R Srigley; M B Amin; D G Bostwick; D J Grignon; M E Hammond
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

2.  Current practice of Gleason grading among genitourinary pathologists.

Authors:  Lars Egevad; William C Allsbrook; Jonathan I Epstein
Journal:  Hum Pathol       Date:  2005-01       Impact factor: 3.466

3.  Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.

Authors:  D F Gleason; G T Mellinger
Journal:  J Urol       Date:  1974-01       Impact factor: 7.450

Review 4.  Histologic grading of prostate cancer: a perspective.

Authors:  D F Gleason
Journal:  Hum Pathol       Date:  1992-03       Impact factor: 3.466

5.  Survival rates of patients with prostatic cancer, tumor stage, and differentiation--preliminary report.

Authors:  J C Bailar; G T Mellinger; D F Gleason
Journal:  Cancer Chemother Rep       Date:  1966-03

6.  Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy.

Authors:  Liang Cheng; Darrell D Davidson; Haiqun Lin; Michael O Koch
Journal:  Cancer       Date:  2007-11-01       Impact factor: 6.860

7.  Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?

Authors:  Jennifer R Stark; Sven Perner; Meir J Stampfer; Jennifer A Sinnott; Stephen Finn; Anna S Eisenstein; Jing Ma; Michelangelo Fiorentino; Tobias Kurth; Massimo Loda; Edward L Giovannucci; Mark A Rubin; Lorelei A Mucci
Journal:  J Clin Oncol       Date:  2009-05-11       Impact factor: 44.544

Review 8.  Rising prostate-specific antigen after primary prostate cancer therapy.

Authors:  John F Ward; Judd W Moul
Journal:  Nat Clin Pract Urol       Date:  2005-04

9.  Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases.

Authors:  Adeboye O Osunkoya; Matthew E Nielsen; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2008-03       Impact factor: 6.394

10.  TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.

Authors:  Anuradha Gopalan; Margaret A Leversha; Jaya M Satagopan; Qin Zhou; Hikmat A Al-Ahmadie; Samson W Fine; James A Eastham; Peter T Scardino; Howard I Scher; Satish K Tickoo; Victor E Reuter; William L Gerald
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701

View more
  46 in total

1.  [The 2014 consensus conference of the ISUP on Gleason grading of prostatic carcinoma].

Authors:  G Kristiansen; L Egevad; M Amin; B Delahunt; J R Srigley; P A Humphrey; J I Epstein
Journal:  Pathologe       Date:  2016-02       Impact factor: 1.011

2.  Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.

Authors:  Trevor A Flood; Nicola Schieda; Daniel T Keefe; Rodney H Breau; Chris Morash; Kevin Hogan; Eric C Belanger; Kien T Mai; Susan J Robertson
Journal:  Virchows Arch       Date:  2016-07-10       Impact factor: 4.064

3.  Detection and grading of prostate cancer using temporal enhanced ultrasound: combining deep neural networks and tissue mimicking simulations.

Authors:  Shekoofeh Azizi; Sharareh Bayat; Pingkun Yan; Amir Tahmasebi; Guy Nir; Jin Tae Kwak; Sheng Xu; Storey Wilson; Kenneth A Iczkowski; M Scott Lucia; Larry Goldenberg; Septimiu E Salcudean; Peter A Pinto; Bradford Wood; Purang Abolmaesumi; Parvin Mousavi
Journal:  Int J Comput Assist Radiol Surg       Date:  2017-06-20       Impact factor: 2.924

4.  Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?

Authors:  Hillary M Ross; Oleksandr N Kryvenko; Janet E Cowan; Jeffry P Simko; Thomas M Wheeler; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2012-09       Impact factor: 6.394

Review 5.  Current perspectives on Gleason grading of prostate cancer.

Authors:  Kenneth A Iczkowski; M Scott Lucia
Journal:  Curr Urol Rep       Date:  2011-06       Impact factor: 3.092

6.  Temporal changes in the pathologic assessment of prostate cancer.

Authors:  M Scott Lucia; Adrie van Bokhoven
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

7.  Automated prostate tissue referencing for cancer detection and diagnosis.

Authors:  Jin Tae Kwak; Stephen M Hewitt; André Alexander Kajdacsy-Balla; Saurabh Sinha; Rohit Bhargava
Journal:  BMC Bioinformatics       Date:  2016-06-01       Impact factor: 3.169

Review 8.  Grading of Prostate Cancer: Past, Present, and Future.

Authors:  Andres Matoso; Jonathan I Epstein
Journal:  Curr Urol Rep       Date:  2016-03       Impact factor: 3.092

9.  Syntaphilin Is a Novel Biphasic Biomarker of Aggressive Prostate Cancer and a Metastasis Predictor.

Authors:  Michael J Hwang; Kelly G Bryant; Jae H Seo; Qin Liu; Peter A Humphrey; Mary Ann C Melnick; Dario C Altieri; Marie E Robert
Journal:  Am J Pathol       Date:  2019-05-09       Impact factor: 4.307

10.  Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.

Authors:  Daniel T Keefe; Nicola Schieda; Soufiane El Hallani; Rodney H Breau; Chris Morash; Susan J Robertson; Kien T Mai; Eric C Belanger; Trevor A Flood
Journal:  Virchows Arch       Date:  2015-07-31       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.